Tobira has reported pharmacokinetic data and results from two phase I pharmacokinetic studies for TAK-652. It is an investigational compound being developed for the treatment of HIV.
Reportedly, these data suggest that TAK-652 is rapidly absorbed and demonstrate relatively good oral bioavailability. The data also suggest that the compound has a long plasma half-life of TBR-652, supporting once-daily dosing.
In both the studies, TBR-652 was found to be safe and well tolerated, when administered over a dose range of 10mg to 800mg in two tablet formulations.
James Sapirstein, CEO of Tobira, said: These two Phase I studies provide encouraging support for TAK-652 as a therapeutic option for the treatment of HIV. We look forward to results from our on-going proof-of-concept study.